DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Johnston SRD, Hegg R, Im SA. et al
Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE.
J Clin Oncol 2021;
39 (01) 79-89
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.